Updated Jul 16, 2026 · Last SEC filing 2026-07-10
Taysha Gene Therapies, Inc. (TSHA) has filed 5 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-10. 4 Form 8-K material event filings were reported by TSHA in the last 90 days. 1 Form 144 notices of proposed sale were filed for TSHA stock. InsiderAlpha tracks every TSHA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001806310 |
|---|
| Form 4 filings (90d) | 5 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-07-10 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D | S — Open-market sale | 200.0K | $6.24 | $1.25M | SEC | |
| Stalfort John A III | Insider | A — Grant or award | 21.3K | $0.00 | — | SEC | |
| Sepp-Lorenzino Laura | Insider | A — Grant or award | 21.3K | $0.00 | — | SEC | |
| Long Alison S | Insider | A — Grant or award | 21.3K | $0.00 | — | SEC | |
| Donenberg Phillip B. | Insider | A — Grant or award | 21.3K | $0.00 | — | SEC | |
| Nagendran Sukumar | President and Head of R&D | M — Option exercise [10b5-1] | 19.0K | $1.71 | $33K | SEC | |
| Nagendran Sukumar | President and Head of R&D | S — Open-market sale [10b5-1] | 200.0K | $4.46 | $892K | SEC | |
| Alam Kamran | CHIEF FINANCIAL OFFICER | S — Open-market sale | 1.7K | $4.52 | $7K | SEC | |
| Nagendran Sukumar | President and Head of R&D | S — Open-market sale | 26.9K | $4.61 | $124K | SEC | |
| Nolan Sean P. | Chief Executive Officer | S — Open-market sale | 41.3K | $4.61 | $190K | SEC | |
| Alam Kamran | CHIEF FINANCIAL OFFICER | S — Open-market sale | 23.8K | $4.61 | $110K | SEC | |
| Alam Kamran | CHIEF FINANCIAL OFFICER | S — Open-market sale | 79.0K | $4.75 | $375K | SEC | |
| Nagendran Sukumar | President and Head of R&D | S — Open-market sale | 89.1K | $4.75 | $423K | SEC | |
| Nolan Sean P. | Chief Executive Officer | S — Open-market sale | 136.8K | $4.75 | $650K | SEC | |
| Nagendran Sukumar | President and Head of R&D | A — Grant or award [10b5-1] | 427.0K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Taysha Gene Therapies, Inc. (TSHA). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Donenberg Phillip B. | 2 | — |
| Stalfort John A III | 2 | — |
| Long Alison S | 2 | — |
| Sepp-Lorenzino Laura | 2 | — |
| Nagendran Sukumar | 1 | $1.25M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in TSHA insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live TSHA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.